Breast carcinoma amplified sequence 1 (BCAS1) was isolated from a region at 20q13 which is amplified in a variety of tumor types and associated with more aggressive tumor phenotypes. Among the genes identified from this region, BCAS1 was found to be highly expressed in three amplified breast cancer cell lines and in one breast tumor without amplification at 20q13.2. However, the BCAS1 gene is not in the common region of maximal amplification and its expression was not detected in the breast cancer cell line MCF7, in which this region is highly amplified. Although not consistently expressed, BCAS1 is a candidate oncogene. It is predicted to encode a protein of 584 amino acids with no significant homology to other proteins.[6]
Maruyama K, Sugano S (1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene. 138 (1–2): 171–4. doi:10.1016/0378-1119(94)90802-8. PMID8125298.
Tanner MM, Tirkkonen M, Kallioniemi A, et al. (1996). "Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer". Cancer Res. 56 (15): 3441–5. PMID8758909.
Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, et al. (1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene. 200 (1–2): 149–56. doi:10.1016/S0378-1119(97)00411-3. PMID9373149.
Correa RG, de Carvalho AF, Pinheiro NA, et al. (2000). "NABC1 (BCAS1): alternative splicing and downregulation in colorectal tumors". Genomics. 65 (3): 299–302. doi:10.1006/geno.2000.6172. PMID10857754.
Beardsley DI, Kowbel D, Lataxes TA, et al. (2003). "Characterization of the novel amplified in breast cancer-1 (NABC1) gene product". Exp. Cell Res. 290 (2): 402–13. doi:10.1016/S0014-4827(03)00353-7. PMID14567997.
